Acrivon Therapeutics (ACRV) vs Cardiff Oncology (CRDF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Acrivon Therapeutics (ACRV) has outperformed Cardiff Oncology (CRDF) over the past year, losing 2.6% versus a loss of 54.6%. Cardiff Oncology is the larger company by market cap ($84.0 million vs $81.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRV | CRDF |
|---|---|---|
| Share price | $1.91 | $1.08 |
| Market cap | $81.85M | $84.02M |
| 1-day change | +2.14% | +1.89% |
| YTD return | -20.75% | -61.57% |
| 1-year return | -2.55% | -54.62% |
| 5-year return | — | -83.13% |
| EPS (TTM) | $-1.88 | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.56 | $3.31 |
| 52-week low | $1.27 | $0.76 |
| Distance from 52-week high | -46.35% | -67.37% |
| Analyst consensus | none | none |
| Avg. price target upside | +502.09% | +437.96% |
| Average volume | 353.72K | 1.04M |
| Shares outstanding | 42.85M | 77.80M |
| Employees | 74 | 30 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRV has outperformed CRDF by 52.1 percentage points over the past year.
About Acrivon Therapeutics
ACRV stock →Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About Cardiff Oncology
CRDF stock →Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees
ACRV vs CRDF FAQ
Which is bigger, Acrivon Therapeutics or Cardiff Oncology?
Cardiff Oncology (CRDF) is larger, with a market capitalization of $84.02M compared with $81.85M for Acrivon Therapeutics (ACRV).
Which stock has performed better over the past year, ACRV or CRDF?
ACRV returned -2.55% over the past 12 months, compared with -54.62% for CRDF (price return, excluding dividends). Past performance does not predict future results.
Are Acrivon Therapeutics and Cardiff Oncology in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Acrivon Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Cardiff Oncology.